Abstract

FIBRATES AND RENAL FUNCTION – AN OVERVIEW

Mridula Das, Manjima G. S., Julia J. J. and Neethu J.*

ABSTRACT

Dyslipidemia has been established as a major risk factor for cardiovascular disease (CVD), which is a major cause of morbidity and mortality in patients with impaired renal function. Fibrates represent an important class of hypolipidemic medications. However, it has been shown that the administration of fibrates (Fenofibrates) in individuals with impaired renal function is associated with an extremely high risk of muscular toxicity. In this review the mechanism of fenofibrate and alterations in the renal function are discussed. Studies on renal impairment after the administration of fenofibrate in patients with normal renal function and impaired renal functions are analysed. In addition, the result of the studies tested the effect of fenofibrate administration which inturn increases the serum creatinine level and decrease in glomerular filtration rate in patients with CKD are reported.

Keywords: Dyslipidemia, Chronic Kidney Disease, Fibrates, Renal Function.